National Institute for Clinical Excellence (NICE): Final Draft OK for Lucentis in Rare Eye Condition

The National Institute for Health and Care Excellence has issued final draft guidance recommending Novartis’ Lucentis (ranibizumab) as a treatment option for sight problems caused by new blood vessels growing at the back of the eye in people with pathological myopia, a rare form of short-sightedness. The treatment should only be prescribed if Novartis makes it available to the NHS under terms agreed with the Department of Health as part of a patient access scheme (PAS), says NICE. The independent appraisal committee examining Lucentis’ use in this indication has decided that an appraisal consultation document is not needed, so the recommendations could go straight to a final appraisal determination.

Help employers find you! Check out all the jobs and post your resume.